Understand Cervical Intraepithelial Neoplasia II (CIN II) and moderate cervical dysplasia. Learn about CIN II diagnosis, treatment, and management. Find information on healthcare, clinical documentation, and medical coding related to CIN II. Explore details on its association with HPV, colposcopy procedures, and follow-up care. This resource offers valuable insights for healthcare professionals, patients, and medical coders seeking information on Cervical Intraepithelial Neoplasia II.
Also known as
Cervical intraepithelial neoplasia II
Moderate dysplasia of the cervix uteri.
Dysplasia of cervix uteri
Abnormal cell growth on the cervix, ranging from mild to severe.
In situ neoplasms of cervix uteri
Early stage cervical cancer that has not spread beyond the surface layer.
Noninflammatory disorders of female genital tract
Covers various non-inflammatory conditions affecting the female reproductive organs.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is CIN II confirmed by biopsy/cytology?
When to use each related code
| Description |
|---|
| Moderately abnormal cervical cells, precancerous lesion. |
| Mildly abnormal cervical cells, may regress or progress. |
| Severely abnormal cervical cells, high-grade precancerous lesion. |
Documentation lacks clarity between CIN I, II, and III, potentially leading to inaccurate coding and under-reporting of severity.
Missing HPV test results or status impacts code selection and risk assessment for cervical cancer screening and management.
Discrepancy between cytology (CIN II) and colposcopy/biopsy findings can affect diagnosis coding and treatment planning.
Q: What are the recommended management strategies for CIN II based on current ASCCP guidelines, considering patient age and colposcopy findings?
A: The American Society for Colposcopy and Cervical Pathology (ASCCP) guidelines recommend different management strategies for CIN II based on patient age, colposcopy findings, and other factors like HPV persistence and patient preference. For women of reproductive age with satisfactory colposcopy, observation with co-testing (HPV testing and cytology) at 12 and 24 months is an acceptable option. If high-risk HPV persists at 24 months, or if there is CIN 2 or worse at either follow-up, excisional treatment is recommended. For women with unsatisfactory colposcopy, immediate excisional treatment (LEEP, cold knife cone) is typically recommended. For postmenopausal women, excisional treatment is generally favored due to the lower likelihood of regression. Explore how the latest ASCCP guidelines influence management decisions for CIN II and consider implementing risk-stratified approaches for improved patient outcomes.
Q: How do I differentiate CIN II from CIN I and CIN III on biopsy, and what are the key histopathological features that distinguish these grades of cervical intraepithelial neoplasia?
A: Differentiating CIN II from CIN I and CIN III relies on careful histological evaluation of cervical biopsy specimens. CIN II is characterized by moderate dysplasia, with abnormal cells occupying the basal two-thirds of the epithelium. CIN I (mild dysplasia) shows abnormal cells limited to the lower third, while CIN III (severe dysplasia/carcinoma in situ) exhibits abnormal cells extending throughout most or all of the epithelial thickness. Key histopathological features to assess include nuclear enlargement, pleomorphism, hyperchromasia, increased nuclear-to-cytoplasmic ratio, and mitotic activity. The distinction between CIN II and CIN III can be challenging and sometimes subjective, requiring expert pathological review in borderline cases. Learn more about the histological criteria for CIN grading and their implications for clinical management.
Patient presents for follow-up of an abnormal Pap smear result indicating atypical squamous cells of undetermined significance cannot exclude high-grade squamous intraepithelial lesion (ASC-H). Colposcopy performed today revealed acetowhite epithelium with punctation and mosaicism within the transformation zone, consistent with cervical intraepithelial neoplasia (CIN). Biopsy confirmed the diagnosis of CIN II (moderate dysplasia). The patient reports no abnormal vaginal bleeding or discharge. She denies pain or discomfort. Relevant medical history includes human papillomavirus (HPV) infection. A thorough discussion regarding treatment options for CIN II, including loop electrosurgical excision procedure (LEEP), cold knife conization (CKC), and ablation, was conducted, outlining the risks and benefits of each procedure. Patient elects to proceed with LEEP. Procedure scheduled and pre-operative instructions provided. Patient education regarding HPV and its association with cervical cancer was reinforced. Follow-up appointment scheduled for post-operative evaluation and cytology in four to six months. ICD-10 code N87.1, Cervical intraepithelial neoplasia grade II, assigned. CPT codes for colposcopy and LEEP will be added upon procedure completion.